Swedish Orphan Biovitrum Total Long Term Liabilities 2019-2024 | BIOVF

Swedish Orphan Biovitrum total long term liabilities for the quarter ending September 30, 2024 were $2.034B, a 19.96% decline year-over-year.

  • Swedish Orphan Biovitrum total long term liabilities for 2023 were $1.986B, a 80.37% increase from 2022.
  • Swedish Orphan Biovitrum total long term liabilities for 2022 were $1.101B, a 43.43% decline from 2021.
  • Swedish Orphan Biovitrum total long term liabilities for 2021 were $1.947B, a 1.29% increase from 2020.

Swedish Orphan Biovitrum Total Long Term Liabilities 2019-2024 | BIOVF

  • Swedish Orphan Biovitrum total long term liabilities for 2023 were $1.986B, a 80.37% increase from 2022.
  • Swedish Orphan Biovitrum total long term liabilities for 2022 were $1.101B, a 43.43% decline from 2021.
  • Swedish Orphan Biovitrum total long term liabilities for 2021 were $1.947B, a 1.29% increase from 2020.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$231.2B
Amgen (AMGN)$160B
Gilead Sciences (GILD)$137.1B
Vertex Pharmaceuticals (VRTX)$123.3B
Bristol Myers Squibb (BMY)$113.2B
CSL (CSLLY)$80.1B
GSK (GSK)$76.6B
Regeneron Pharmaceuticals (REGN)$76.1B
Argenex SE (ARGX)$39.3B
Alnylam Pharmaceuticals (ALNY)$32.5B
BioNTech SE (BNTX)$28.3B
BeiGene (ONC)$23.9B
Biogen (BIIB)$20.1B
Illumina (ILMN)$15.4B
Insmed (INSM)$15B
Genmab (GMAB)$14.9B
Genmab (GNMSF)$14.7B
Incyte (INCY)$13.8B
Intra-Cellular Therapies (ITCI)$13.7B
BioMarin Pharmaceutical (BMRN)$13.1B
Moderna (MRNA)$13B
Sarepta Therapeutics (SRPT)$10.4B
Bio-Techne Corp (TECH)$10.4B
Vaxcyte (PCVX)$10.3B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.2B
Repligen (RGEN)$9.1B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.6B